Skip to main content
Unchecking box will stop auto data updates
Cboe BZX Real-Time Last Sale USD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 17.31
Day High 18.00
Open:17.45
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

Description
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. The company's proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

Array BioPharma Announces 15.3 Months Median Overall Survival from the Safety Lead-in of the Phase 3 BEACON CRC Trial of the Combination BRAFTOVI®, MEKTOVI® and ERBITUX® in BRAF-Mutant Metastatic Colorectal Cancer
PR Newswire - Mon Jan 14, 4:03PM CST
PR Newswire - PRNW
Mon Jan 14, 4:03PM CST
BOULDER, Colo. , Jan. 14, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced updated safety and efficacy results, including mature overall survival (OS), from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of BRAFTOVI ® (encorafenib), a BRAF inhibitor, MEKTOVI ® (binimetinib), a MEK inhibitor and ERBITUX ® (cetuximab), an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (mCRC). The results showed that mature median OS was 15.3 months (95% CI, 9.6–not reached) for patients treated with the triplet. These data will be presented on Saturday, January 19 at the ASCO 2019 Gastrointestinal Cancers Symposium in San Francisco, California .
Array BioPharma Announces 15.3 Months Median Overall Survival from the Safety Lead-in of the Phase 3 BEACON CRC Trial of the Combination BRAFTOVI®, MEKTOVI® and ERBITUX® in BRAF-Mutant Metastatic Colorectal Cancer
PR Newswire - Mon Jan 14, 4:03PM CST
PR Newswire - CMTX
Mon Jan 14, 4:03PM CST
Array BioPharma Inc. (Nasdaq: ARRY) today announced updated safety and efficacy results, including mature overall survival (OS), from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of BRAFTOVI® (encorafenib), a BRAF inhibitor, MEKTOVI® (binimetinib), a MEK inhibitor and ERBITUX® (cetuximab), an anti-EGFR antibody, in patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC). The results showed that mature median OS was 15.3 months (95% CI, 9.6-not reached) for patients treated with the triplet. These data will be presented on Saturday, January 19 at the ASCO 2019 Gastrointestinal Cancers Symposium in San Francisco, California.
Array BioPharma to Present at the 37th Annual J.P. Morgan Healthcare Conference
PR Newswire - Thu Dec 20, 3:05PM CST
PR Newswire - CMTX
Thu Dec 20, 3:05PM CST
Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco. The public is welcome to participate in the conference through a webcast on the Array BioPharma website.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 13.06 +34.23% increase
on 12/24/18
Period Open:15.13
Price movement based on the high, low and last over the given period.
18.19 -3.63% decrease
on 01/15/19
+2.40 (+15.86%) increase
since 12/18/18
3-Month 13.06 +34.23% increase
on 12/24/18
Period Open:15.46
Price movement based on the high, low and last over the given period.
18.19 -3.63% decrease
on 01/15/19
+2.07 (+13.39%) increase
since 10/18/18
52-Week 12.56 +39.57% increase
on 10/11/18
Period Open:12.88
Price movement based on the high, low and last over the given period.
20.21 -13.26% decrease
on 06/21/18
+4.65 (+36.10%) increase
since 01/18/18

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2019.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

More stories below advertisement